Ricci, Costantino; Ambrosi, Francesca; Franceschini, Tania; Giunchi, Francesca; Franchini, Eugenia; Massari, Francesco; Mollica, Veronica; Bianchi, Federico Mineo; Colecchia, Maurizio; Acosta, Andres Martin; Fiorentino, Michelangelo, Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma?, «PATHOLOGY, RESEARCH AND PRACTICE», 2023, 241, pp. 154269 - 154269 [Scientific article]
Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco, A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy, «PATHOLOGY RESEARCH AND PRACTICE», 2022, 236, pp. 153978 - 153983 [Scientific article]
Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F., A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents, «ANTI-CANCER DRUGS», 2022, 33, pp. e43 - e51 [Scientific article]
Pal S.K.; Uzzo R.; Karam J.A.; Master V.A.; Donskov F.; Suarez C.; Albiges L.; Rini B.; Tomita Y.; Kann A.G.; Procopio G.; Massari F.; Zibelman M.; Antonyan I.; Huseni M.; Basu D.; Ci B.; Leung W.; Khan O.; Dubey S.; Bex A., Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial, «THE LANCET», 2022, 400, pp. 1103 - 1116 [Scientific article]Open Access
Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F., Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study, «CANCERS», 2022, 14, Article number: 4142 , pp. 1 - 9 [Scientific article]Open Access
Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System, «CANCERS», 2022, 14, Article number: 4610 , pp. 1 - 13 [Scientific article]Open Access
Santoni M.; Massari F.; Rizzo A.; Mollica V.; Cimadamore A.; Montironi R.; Battelli N., Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis, «TUMORI», 2022, na, pp. 030089162210903 - 030089162210909 [Scientific article]
Rebuzzi S.E.; Cerbone L.; Signori A.; Santoni M.; Murianni V.; De Giorgi U.; Procopio G.; Porta C.; Milella M.; Basso U.; Massari F.; Maruzzo M.; Iacovelli R.; Battelli N.; Carmisciano L.; Banna G.L.; Buti S.; Fornarini G., Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2022, 14, Article number: 17588359221079580 , pp. 1 - 12 [Scientific article]Open Access
Rizzo A.; Mollica V.; Santoni M.; Massari F., Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis, «IMMUNOTHERAPY», 2022, 14, pp. 617 - 625 [Scientific article]
Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F., Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw, «CURRENT ONCOLOGY», 2022, 29, pp. 1709 - 1722 [Scientific article]Open Access
Rizzo A.; Mollica V.; Massari F., Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma, «JAMA ONCOLOGY», 2022, 8, pp. 783 - 784 [Scientific article]
Santoni, M.; Massari, F.; Bracarda, S.; Grande, E.; Matrana, M. R.; Rizzo, M.; De Giorgi, U.; Basso, U.; Aurilio, G.; Incorvaia, L.; Martignetti, A.; Molina-Cerrillo, J.; Mollica, V.; Rizzo, A.; Battelli, N., Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors, «EUROPEAN UROLOGY FOCUS», 2022, 8, pp. 1696 - 1702 [Scientific article]Open Access
Rizzo A.; Mollica V.; Santoni M.; Massari F., Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 6356 , pp. 1 - 3 [Scientific article]Open Access
Medici, Federica; Siepe, Giambattista; Strigari, Lidia; Massari, Francesco; Buwenge, Milly; Bisello, Silvia; Castellucci, Paolo; Fanti, Stefano; Cammelli, Silvia; Morganti, Alessio Giuseppe, CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report, «MOLECULAR AND CLINICAL ONCOLOGY», 2022, 16, Article number: 85 , pp. 1 - 5 [Scientific article]Open Access
Rizzo A.; Mollica V.; Santoni M.; Massari F., Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 482 - 487 [Scientific article]
